In a 4-week randomized controlled study in patients with T2D (n = 60), empagliflozin significantly reduced 24-h MG and PPG, compared with placebo, and increased the percentage of time spent with glucose in the target range (≥70 to <180 mg/dL).21 The patient population consisted of Japanese patients who were drug naïve or treated with one OAD, which differed from this study in which patients were treated with either metformin monotherapy or insulin with or without up to two OADs, with results additionally analyzed in these strata. This evidence concerns the gene INS and type 2 diabetes mellitus.